Package Leaflet: Information for the patient
Fycompa 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg film‑coated tablets
Perampanel
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet:
1. What Fycompa is and what it is used for
2. What you need to know before you take Fycompa
3. How to take Fycompa
4. Possible side effects
5. How to store Fycompa
6. Contents of the pack and other information
1. What Fycompa is and what it is used for
Fycompa contains a medicine called perampanel. It belongs to a group of medicines called anti epileptics. These medicines are used to treat epilepsy - where someone has repeated fits (seizures). It has been given to you by your doctor to reduce the number of fits that you have.
Fycompa is used in association with other antiepileptic drugs to treat certain forms of epilepsy:
In adults, adolescents (aged 12 years and older), and children (from 4 to 11 years)
In adults and adolescents (aged 12 years and older), and children (from 7 to 11 years)
2. What you need to know before you take Fycompa
DO NOT TAKE Fycompa:
- If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking perampanel.
Warnings and precautions
Talk to your doctor or pharmacist before taking Fycompa if you have liver problems or moderate or severe kidney problems.
You should not take Fycompa if you have serious liver problems or moderate or serious kidney problems.
Before taking this medicine you should tell your doctor if you have a history of alcoholism or drug dependence.
Cases of increased liver enzymes have been reported in some patients taking Fycompa in combination with other antiepileptic drugs.
A small number of people being treated with anti‑epileptics have had thoughts of harming or killing themselves. If at any time you have these thoughts, contact your doctor straight away.
Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens ‑ Johnson Syndrome (SJS) have been reported with the use of perampanel.
- Stevens ‑ Johnson Syndrome (SJS) can appear initially as reddish target- like spots or circular patches often with central blisters on the trunk. Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur. These serious skin rashes are often preceded by fever and/or flu-like symptoms. The rashes may progress to widespread peeling of the skin and life-threatening complications or be fatal.
If you experience any of the above after taking Fycompa (or you are not sure) talk to your doctor or pharmacist.
Children
Fycompa is not recommended for children aged under 4. The safety and effectiveness are not yet known in children under 4 years of age for partial seizures and under 7 years of age in generalised seizures.
Other medicines and Fycompa
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. Taking Fycompa with certain other medicines may cause side effects or affect how they work. Do not start or stop other medicines without talking to your doctor or pharmacist.
Tell your doctor if you are taking hormonal contraceptives. Fycompa may make certain hormonal contraceptives such as levonorgestrel less effective. You should use other forms of safe and effective contraception (such as a condom or coil) when taking Fycompa. You should continue doing this for one month after stopping treatment. Discuss with your doctor what may be appropriate contraception for you.
Fycompa with alcohol
Speak to your doctor before drinking alcohol. Be careful about consuming alcohol with epilepsy medicines including Fycompa.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Do not stop treatment without first discussing it with your doctor.
It is not known whether the ingredients of Fycompa can pass into breast milk.
The doctor will weigh up the benefit and risks to your baby of taking Fycompa while you are breast‑feeding.
Driving and using machines
Do not drive or use machines until you know how Fycompa affects you.
You must talk to your doctor about the effect of your epilepsy on driving and using machines.
Fycompa contains lactose
Fycompa contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
3. How to take Fycompa
Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
How much to take
Adults, adolescents (aged 12 years and older) in treating partial seizures and generalised seizures:
The usual starting dose is 2 mg once a day before you go to bed.
The following table summarises the recommended doses in treating partial seizures in children 4 to 11 years of age and generalised seizures in children 7 to 11 years of age. More details are provided below the table.
Children weighing:
More than 30 kg
20 kg to less than 30 kg
Less than 20 kg
Recommended starting dose
2 mg/day
1 mg/day
1 mg/day
Recommended maintenance dose
4 – 8 mg/day
4 – 6 mg/day
2 – 4 mg/day
Recommended maximum dose
12 mg/day
8 mg/day
6 mg/day
Children (from 4 to 11 years of age) weighing 30 kg or more in treating partial seizures:
The usual starting dose is 2 mg once a day before you go to bed.
Children (from 4 to 11 years of age) weighing 20 kg and less than 30 kg in treating partial seizures:
The usual starting dose is 1 mg once a day before you go to bed.
- Your doctor may increase this in 1 mg steps to a maintenance dose between 4 mg and 6 mg - depending on your response. Depending upon individual clinical response and tolerability, the dose may be increased to a maximum dose of 8 mg/day.
Children (from 4 to 11 years of age) weighing less than 20 kg in treating partial seizures:
The usual starting dose is 1 mg once a day before you go to bed.
Children (from 7 to 11 years of age) weighing 30 kg or more in treating generalised seizures:
The usual starting dose is 2 mg once a day before you go to bed.
- Your doctor may increase this in 2 mg steps to a maintenance dose between 4 mg and 8 mg - depending on your response. Depending upon individual clinical response and tolerability, the dose may be increased to a maximum dose of 12 mg/day.
Children (from 7 to 11 years of age) weighing 20 kg and less than 30 kg in treating generalised seizures:
The usual starting dose is 1 mg once a day before you go to bed.
- Your doctor may increase this in 1 mg steps to a maintenance dose between 4 mg and 6 mg - depending on your response. Depending upon individual clinical response and tolerability, the dose may be increased to a maximum dose of 8 mg/day.
Children (from 7 to 11 years of age) weighing less than 20 kg in treating generalised seizures:
The usual starting dose is 1 mg once a day before you go to bed.
How to take
Swallow the tablet whole with a glass of water. You can take Fycompa with or without food. Do not chew, crush or split the tablet. The tablets cannot be split accurately as there is no break line.
If you take more Fycompa than you should
If you have taken more Fycompa than you should contact your doctor straight away. You may experience confusion, agitation, aggressive behaviour and depressed level of consciousness.
If you forget to take Fycompa
If you stop taking Fycompa
Take Fycompa for as long as your doctor recommends. Do not stop unless your doctor advises you to. Your doctor may reduce your dose slowly to avoid your fits (seizures) coming back or getting worse.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
A small number of people being treated with anti‑epileptics have had thoughts of harming or killing themselves. If at any time you have these thoughts, contact your doctor straight away.
Very common (may affect more than 1 user in 10) are:
Common (may affect more than 1 user in 100) are:
Uncommon (may affect more than 1 user in 1000) are:
Not known (the frequency of this side effect cannot be estimated from the available data) are:
Stop using perampanel if you develop these symptoms and contact your doctor or seek medical attention immediately. See also section 2.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the HPRA Pharmacovigilance
Website: www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Fycompa
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of the month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6. Contents of the pack and other information
What Fycompa contains
The active substance is perampanel. Each film‑coated tablet contains 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, or 12 mg perampanel.
The other ingredients are:
Tablet core (2 mg and 4 mg tablets):
Lactose monohydrate, low-substituted hydroxypropyl cellulose, povidone, magnesium stearate (E470b)
Tablet core (6 mg, 8 mg, 10 mg and 12 mg tablets)
Lactose monohydrate, low-substituted hydroxypropyl cellulose, povidone, microcrystalline cellulose, magnesium stearate (E470b)
Film coating (2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg tablets)
Hypromellose 2910, talc, Macrogol 8000, titanium dioxide (E171), colourants*
*The colourants are:
2 mg tablet: Ferric Oxide, Yellow (E172), Ferric Oxide, Red (E172)
4 mg tablet: Ferric Oxide, Red (E172)
6 mg tablet: Ferric Oxide, Red (E172)
8 mg tablet: Ferric Oxide, Red (E172), Ferric Oxide, Black (E172)
10 mg tablet: Ferric Oxide, Yellow (E172), FD&C Blue #2 Indigo carmine aluminium lake (E132)
12 mg tablet: FD&C Blue #2 Indigo carmine aluminium lake (E132)
What Fycompa looks like and contents of the pack
All strengths of Fycompa are round, biconvex film‑coated tablets
2 mg: orange, marked with E275 on one side and 2 on other side
4 mg: red, marked with E277 on one side and 4 on other side
6 mg: pink, marked with E294 on one side and 6 on other side
8 mg: purple, marked with E295 on one side and 8 on other side
10 mg: green, marked with E296 on one side and 10 on other side
12 mg: blue, marked with E297 on one side and 12 on other side
Fycompa is available in packs of:
2 mg tablet – pack of 7, 28 and 98
4 mg, 6 mg, 8 mg, 10 mg, 12 mg tablets – packs of 7, 28, 84 and 98
Not all pack sizes may be marketed
Marketing Authorisation Holder
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
e-mail: medinfo_de@eisai.net
Manufacturer
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Eisai SA/NV
Tél/Tel: +32 (0)800 158 58
Lietuva
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Vokietija)
България
Eisai GmbH
Teл.: + 49 (0) 69 66 58 50
(Германия)
Luxembourg/Luxemburg
Eisai SA/NV
Tél/Tel: +32 (0)800 158 58
(Belgique/Belgien)
Česká republika
Eisai GesmbH organizačni složka
Tel: + 420 242 485 839
Magyarország
Ewopharma Hungary Kft.
Tel.: + 36 1 200 46 50
Danmark
Eisai AB
Tlf: + 46 (0) 8 501 01 600
(Sverige)
Malta
Cherubino LTD
Tel: +356 21343270
Deutschland
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
Nederland
Eisai B.V.
Tel: + 31 (0) 900 575 3340
Eesti
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Saksamaa)
Norge
Eisai AB
Tlf: + 46 (0) 8 501 01 600
(Sverige)
Ελλάδα
Arriani Pharmaceutical S.A.
Τηλ: + 30 210 668 3000
Österreich
Eisai GesmbH
Tel: + 43 (0) 1 535 1980-0
España
Eisai Farmacéutica, S.A.
Tel: + (34) 91 455 94 55
Polska
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Niemcy)
France
Eisai SAS
Tél: + (33) 1 47 67 00 05
Portugal
Eisai Farmacêtica, Unipessoal Lda
Tel: + 351 214 875 540
Hrvatska
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Njemačka)
România
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Germania)
Ireland
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Germany)
Slovenija
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Nemčija)
Ísland
Eisai AB
Sími: + 46 (0)8 501 01 600
(Svíþjóð)
Slovenská republika
Eisai GesmbH organizačni složka
Tel.: + 420 242 485 839
(Česká republika)
Italia
Eisai S.r.l.
Tel: + 39 02 5181401
Suomi/Finland
Eisai AB
Puh/Tel: + 46 (0) 8 501 01 600
(Ruotsi)
Κύπρος
Arriani Pharmaceuticals S.A.
Τηλ: + 30 210 668 3000
(Ελλάδα)
Sverige
Eisai AB
Tel: + 46 (0) 8 501 01 600
Latvija
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Vācija)
United Kingdom (Northern Ireland)
Eisai GmbH
Tel: + 49 (0) 69 66 58 50
(Germany)
This leaflet was last revised in 04/2023
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Fyco/0026/2023